NCT06735833 MMA Embolization for Refractory Chronic Migraine
| NCT ID | NCT06735833 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cerenovus, Part of DePuy Synthes Products, Inc. |
| Condition | Migraine Disorders |
| Study Type | INTERVENTIONAL |
| Enrollment | 70 participants |
| Start Date | 2025-04-23 |
| Primary Completion | 2026-12-25 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 70 participants in total. It began in 2025-04-23 with a primary completion date of 2026-12-25.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a prospective, multi-center, feasibility study to investigate safety and effectiveness of TRUFILL n-BCA liquid embolic system in bilateral middle meningeal artery (MMA) embolization for the treatment of refractory chronic migraine.
Eligibility Criteria
Participant Inclusion Criteria, Candidates for this study must meet ALL the following inclusion criteria: 1. Patient is between 18 and 65 years of age (inclusive) at the time of consent 2. Age of onset of Chronic Migraine \<= 64 years 3. Age of onset of migraine diagnosis \< 50 years 4. Patient has a current diagnosis of refractory migraine 5. Patient has a current diagnosis of Chronic migraine Participant Exclusion Criteria, Candidates will be excluded from participation if ANY of the following apply: 1. Patients with a history for the last 2 years of other primary headache types, or secondary headache types except medication overuse headache 2. Patients with diagnosis of hemiplegic migraine or migrainous infarct 3. Patients with current regular use of Opioids, Cannabis, Medical Marijuana, etc 4. Women who are pregnant, lactating, or who are of childbearing age 5. Current involvement in an investigational (drug, device, etc.) clinical trial that may confound study endpoints. Participants in observational, natural history, and/or epidemiological studies not involving intervention are eligible. Sponsor approval is required
Contact & Investigator
Study Contact
✉ RA-MIGRAINECNV202302@ITS.JNJ.comFrequently Asked Questions
Who can join the NCT06735833 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Migraine Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06735833 currently recruiting?
Yes, NCT06735833 is actively recruiting participants. Contact the research team at RA-MIGRAINECNV202302@ITS.JNJ.com for enrollment information.
Where is the NCT06735833 trial being conducted?
This trial is being conducted at Walnut Creek, United States, Hartford, United States, New York, United States, Stony Brook, United States and 3 additional locations.
Who is sponsoring the NCT06735833 clinical trial?
NCT06735833 is sponsored by Cerenovus, Part of DePuy Synthes Products, Inc.. The trial plans to enroll 70 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.